米托蒽醌单独及其联合美罗华治疗恶性淋巴瘤的疗效探讨

目的：探讨米托蒽醌单独及其联合美罗华治疗非霍奇金恶性淋巴瘤(NHL)的疗效。方法随机选取该院2007年10月—2013年10月收治的40例非霍奇金恶性淋巴瘤患者，抽签随机分为对照组和观察组，每组各20例。对照组患者给予含米托蒽醌化疗方案治疗，观察组采用含米托蒽醌化疗方案联合美罗华治疗，比较两组治疗效果。结果观察组治疗有效率95.0%较对照组70.0%明显较高，差异有统计学意义(P<0.05)，观察组2年、5年的无复发生存率(RFS)和总生存率(OS)均高于对照组；观察组不良反应率16.36%较对照组32.73%显著较低，差异有统计学意义(P<0.05)。结论含米托蒽醌化疗方案联合美罗华能有效治疗非霍奇金恶性淋巴瘤，提高无复发生存率和总生存率，且未引起其他不良反应症状，耐受性较好，临床综合效果较为显著。

Mitoxantrone Alone Versus Mitoxantrone Combined with Rituximab in the Treatment of Malignant Lymphoma

Objective To observe the effect of mitoxantrone alone and it combined with rituximab in the treatment of non-Hodgkin’s lymphoma (NHL). Methods 40 cases with NHL admitted in our hospital from October 2007 to October 2013 were selected and randomly divided into control group and observation group, 20 cases in each group by drawing lots. The control group were treated by mitoxantrone chemotherapy regimen, the observation group were treated by mitoxantrone chemotherapy regimen combined with rituximab. The therapeutic effects of the two groups were compared. Results The ef-fective rate in the observation group was significantly higher than that in the control group (95.0% vs 70.0%) with statisti-cally significant difference (P<0.05). The 2-year and 5-year recurrence-free survival (RFS) was higher in the observation group than that in the control group. The 2-year and 5-year overall survival (OS) was higher in the observation group than that in the control group. The incidence of adverse reactions was much lower in the observation group than that in the con-trol group (16.36%vs 32.73%) with statistically significant difference (P<0.05). Conclusion Mitoxantrone chemotherapy reg-imen combined with rituximab is effective in the treatment of NHL, which can increase the RFS and OS with good tolerance and significant clinical effect but has no other adverse reactions.